Abstract
Clinical performance of YD-I (Daicel Chemical Ind. Ltd., Tokyo, Japan), a newly developed patient controller for hemofiltration (HF), was studied in the 66 clinical trials. Hemofresh (Daicel Chemical Ind. Ltd., Tokyo, Japan) was employed as a filter and at least 18L of body fluid exchange was performed with post dilution method. The indicated values of the device for total ultrafiltrate and total substitution fluid were compared with the actually measured values. The errors between the both values were 0.3±0.22 and 0.4±0.29% (Mean±SD), respectively, which proves the high precision of the volumetric measuring system utilyzing a microcomputer. It is proved that an easy and safe operation is possible with YD-I.
